Sanofi to boost early-stage research with ‘real world’ evidence
pharmafile | June 23, 2011 | News story | Research and Development | Sanofi, patient data, pharma research
Sanofi is aiming to maximise its R&D investment by including ‘real world’ evidence in its product development strategy.
The company is collaborating with US pharmacy benefit management firm Medco to include information generated during product development and throughout products’ lifecycles in its research.
Sanofi said this would help more precisely identify patient populations for which its drugs candidates could be most effective.
The partners will also aim to better – and earlier – define the relative value of potential products and thus meet payer, as well as medical, needs head on.
Sanofi’s chief medical officer Jean-Pierre Lehner said its work with Medco would help “close the gap between fundamental research and real world clinical setting”.
It would also “bring the transformative change to the drug development process required to improve the quality of patient care, while effectively meeting payer and other stakeholder evidence requirements,” he added.
The global collaboration will also involve Medco subsidiary, and global scientific and medical affairs organisation, United BioSource Corporation.
Under the terms of the multi-year deal, Medco and UBC will provide real world input and comparative data for Sanofi to use in its product development strategy.
“Some products, that seemed to hold promise in early research, might not deliver the intended results when used in real-world practice,” said Dr Rob Epstein, Medco’s President Advanced Clinical Science and Research and chief clinical research and development officer.
“In the framework of this agreement real world data will be used to develop products that demonstrate value in real world settings, enabling Sanofi to support high quality, cost effective care.”
Dominic Tyer
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
